Performance of the Boditech iCHROMA Covid-19 IgG antibody assay with the external quality control for UK NIBSC (National Institute of Biological Standards and Control)
Abstract:Background: There is a need for laboratories to participate in EQA schemes to achieve a harmonization of test results and to improve serological testing and research on COVID-19 and SARS-CoV-2. The Boditech iCHROMA point of care immunoassay analyser has a Covid-19 antibody assay for the qualitative determination of IgG antibodies in human whole blood/serum/plasma. The National Institute for Biological Standards and Control (NIBSC) in the United Kingdom has a portfolio of reference and research reagents, includ… Show more
“…Covid-19 Infected subject (Day 1-100 post infection): Blood samples had been taken from a subject who suffered mild symptoms confirmed by PCR and antigen tests on day 1,2, 3,4,5,6,7,8,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26…”
Section: Methodsmentioning
confidence: 99%
“…The study concluded that there was 100% agreement of the presence of IgG antibodies in the samples to Covid-19 between the Boditech iCHROMA Covid 19 IgG antibody assay method and the Abbot Architect SARS-CoV-2 IgG method (Clinical Sensitivity). In addition, there was 90% agreement in the absence of Covid-19 IgG antibodies in the samples between the Boditech iCHROMA Covid 19 IgG antibody assay and the Abbot Architect SARS-CoV-2 IgG (Clinical Specificity) [12]. In another study, the performance of the Boditech iCHROMA Covid 19 IgG antibody assay was assessed using the NIBSC (National Institute for Biological Standards and Control) reference material.…”
Background: Coronavirus disease 2019 (COVID-19) is an emerging threat affecting millions of people worldwide. This study aims to assess the serologic profiles and time kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with COVID-19 using the Boditech iCHROMA fluorescence immunoassay (FIA) method. Methods: Samples were collected from 43 subjects and analyzed for IgG antibodies against SARS-CoV-2 using the Boditech iCHROMA FIA. The iCHROMA processes the signal using a cut off index of 0.9 – 1.1, results <0.9 are interpreted as negative, results between 0.9 and 1.1 are interpreted as indeterminate and results >1.1 are interpreted as positive. Longitudinal samples were collected on days between day 1- day 100 post onset of symptoms in 1 subject, single samples collected on days 40-90 post infection in 30 subjects, and single samples collected at 3 time points (pre vaccination, 8-18 days post vaccination and 20-28 days post vaccination) collected from 12 subjects non-infected and previously infected. Results: The Covid-19 IgG concentration was detected (positive and cut off index above 1.1) on day 11 and remained consistently elevated for another 100 days of measurement in the sera of the single infected subject. The IgG cut off indices between day 20 and 100 ranged between 26.8 and 46.7, with a mean of 36.5. In the sera of the 30 patients infected with Covid-19 collected 40 – 90 days post infection, IgG antibodies were detected in all the samples. The IgG cut off indices ranged between 14.0 and 32.60, with a mean of 20.65. Of the twelve subjects who were vaccinated, eight had not been previously infected, while 4 had been previously infected. All 4 (100%) previously infected subjects seroconverted by the first time point (8-18 days post vaccination), whilst only 1/8 (12.5%) of the non-infected subjects seroconverted by the first time point (8-18 days post vaccination). By the second time point (20 - 28 days post vaccination), 2/12 subjects (17%) had failed to seroconvert, whilst 10/12 (83%) of the subjects had seroconverted. In addition, a previously infected subject whose IgG antibodies had dropped to a very low-level, after receiving the first dose of vaccination his IgG antibodies had gone back to his previous antibody levels at the first time point (8-18 days post vaccination). Conclusion: The Boditech iCHROMA FIA method for antibody testing is useful in detecting SARS-CoV-2 in a variety of situations at different time points but has its limitations with regards to determining the difference between previously infected and vaccinated individuals.
“…Covid-19 Infected subject (Day 1-100 post infection): Blood samples had been taken from a subject who suffered mild symptoms confirmed by PCR and antigen tests on day 1,2, 3,4,5,6,7,8,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26…”
Section: Methodsmentioning
confidence: 99%
“…The study concluded that there was 100% agreement of the presence of IgG antibodies in the samples to Covid-19 between the Boditech iCHROMA Covid 19 IgG antibody assay method and the Abbot Architect SARS-CoV-2 IgG method (Clinical Sensitivity). In addition, there was 90% agreement in the absence of Covid-19 IgG antibodies in the samples between the Boditech iCHROMA Covid 19 IgG antibody assay and the Abbot Architect SARS-CoV-2 IgG (Clinical Specificity) [12]. In another study, the performance of the Boditech iCHROMA Covid 19 IgG antibody assay was assessed using the NIBSC (National Institute for Biological Standards and Control) reference material.…”
Background: Coronavirus disease 2019 (COVID-19) is an emerging threat affecting millions of people worldwide. This study aims to assess the serologic profiles and time kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with COVID-19 using the Boditech iCHROMA fluorescence immunoassay (FIA) method. Methods: Samples were collected from 43 subjects and analyzed for IgG antibodies against SARS-CoV-2 using the Boditech iCHROMA FIA. The iCHROMA processes the signal using a cut off index of 0.9 – 1.1, results <0.9 are interpreted as negative, results between 0.9 and 1.1 are interpreted as indeterminate and results >1.1 are interpreted as positive. Longitudinal samples were collected on days between day 1- day 100 post onset of symptoms in 1 subject, single samples collected on days 40-90 post infection in 30 subjects, and single samples collected at 3 time points (pre vaccination, 8-18 days post vaccination and 20-28 days post vaccination) collected from 12 subjects non-infected and previously infected. Results: The Covid-19 IgG concentration was detected (positive and cut off index above 1.1) on day 11 and remained consistently elevated for another 100 days of measurement in the sera of the single infected subject. The IgG cut off indices between day 20 and 100 ranged between 26.8 and 46.7, with a mean of 36.5. In the sera of the 30 patients infected with Covid-19 collected 40 – 90 days post infection, IgG antibodies were detected in all the samples. The IgG cut off indices ranged between 14.0 and 32.60, with a mean of 20.65. Of the twelve subjects who were vaccinated, eight had not been previously infected, while 4 had been previously infected. All 4 (100%) previously infected subjects seroconverted by the first time point (8-18 days post vaccination), whilst only 1/8 (12.5%) of the non-infected subjects seroconverted by the first time point (8-18 days post vaccination). By the second time point (20 - 28 days post vaccination), 2/12 subjects (17%) had failed to seroconvert, whilst 10/12 (83%) of the subjects had seroconverted. In addition, a previously infected subject whose IgG antibodies had dropped to a very low-level, after receiving the first dose of vaccination his IgG antibodies had gone back to his previous antibody levels at the first time point (8-18 days post vaccination). Conclusion: The Boditech iCHROMA FIA method for antibody testing is useful in detecting SARS-CoV-2 in a variety of situations at different time points but has its limitations with regards to determining the difference between previously infected and vaccinated individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.